- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07301255
ENV-294 vid måttlig till svår astma: En 12-veckorsstudie hos vuxna
En fas 2-studie, randomiserad, dubbelblind, placebokontrollerad, med parallella grupper under 12 veckor, för att utvärdera effekten, säkerheten och farmakokinetiken hos ENV-294 hos vuxna deltagare med måttlig till svår astma
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA).
Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Clinical Operations
- E-post: env-294.clinicaltrials@enveda.com
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35209
- Rekrytering
- Enveda Investigative Site
-
-
California
-
Los Angeles, California, Förenta staterna, 90025
- Rekrytering
- Enveda Investigative Site
-
San Jose, California, Förenta staterna, 95117
- Rekrytering
- Enveda Investigative Site
-
West Hills, California, Förenta staterna, 91307
- Rekrytering
- Enveda Investigative Site
-
-
Colorado
-
Colorado Springs, Colorado, Förenta staterna, 80907
- Rekrytering
- Enveda Investigative Site
-
-
Florida
-
Hialeah, Florida, Förenta staterna, 33012
- Rekrytering
- Enveda Investigative Site
-
Miami, Florida, Förenta staterna, 33135
- Rekrytering
- Enveda Investigative Site
-
-
Georgia
-
Albany, Georgia, Förenta staterna, 31707
- Rekrytering
- Enveda Investigative Site
-
-
Illinois
-
Maryville, Illinois, Förenta staterna, 62062
- Rekrytering
- Enveda Investigative Site
-
-
Kansas
-
Kansas City, Kansas, Förenta staterna, 66160
- Rekrytering
- Enveda Investigative Site
-
-
Kentucky
-
Owensboro, Kentucky, Förenta staterna, 42301
- Rekrytering
- Enveda Investigative Site
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Rekrytering
- Enveda Investigative Site
-
-
Michigan
-
Southfield, Michigan, Förenta staterna, 48075
- Rekrytering
- Enveda Investigative Site
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63141
- Rekrytering
- Enveda Investigative Site
-
-
New York
-
The Bronx, New York, Förenta staterna, 10455
- Rekrytering
- Enveda Investigative Site
-
-
Oregon
-
Clackamas, Oregon, Förenta staterna, 97015
- Rekrytering
- Enveda Investigative Site
-
Medford, Oregon, Förenta staterna, 97504
- Rekrytering
- Enveda Investigative Site
-
-
South Carolina
-
North Charleston, South Carolina, Förenta staterna, 29406
- Rekrytering
- Enveda Investigative Site
-
-
Texas
-
McKinney, Texas, Förenta staterna, 75069
- Rekrytering
- Enveda Investigative Site
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53792
- Rekrytering
- Enveda Investigative Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Able to read, understand, and sign an informed consent form before any study procedures
- Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months
- Receiving stable treatment with an inhaled corticosteroid (ICS) plus a long-acting beta₂-agonist (LABA) for at least 2 months before screening
- Pre-bronchodilator FEV₁ between 50% and 80% of predicted normal at screening and baseline
- Demonstrated bronchodilator reversibility
- ACQ-5 score ≥1.25 to ≤3.0 at screening and baseline
- History of at least one asthma exacerbation in the past 12 months requiring systemic corticosteroids or hospitalization/emergency care
Exclusion Criteria:
- Recent moderate or severe asthma exacerbation (within 4 weeks before screening)
- History of life-threatening asthma
- Other significant pulmonary disease
- Recent bronchial thermoplasty (within 2 years)
- Uncontrolled current or recurrent concomitant illness
- Recent use of biologic therapies for asthma (within 6 months or 5 half-lives)
- Require immunosuppressive medications or frequent systemic corticosteroids
- Current smokers or former smokers with significant smoking history
- Uncontrolled hypertension
- Significant hepatic impairment
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: ENV-294 Treatment Arm
ENV-294 will be administered to those participants randomized to the treatment arm. |
ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks. |
|
Placebo-jämförare: Placebo Arm
A placebo will be administered to those participants randomized to the placebo arm. |
Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence and Severity of Adverse Events
Tidsram: From first dose through approximately 16 weeks
|
Number and percentage of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuation of study drug. |
From first dose through approximately 16 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Loss of Asthma Control Events
Tidsram: Baseline to Week 12
|
Number and percentage of participants experiencing a loss of asthma control (LOAC) event during the treatment period, defined according to protocol-specified criteria |
Baseline to Week 12
|
|
Time to Loss of Asthma Control
Tidsram: Baseline to Week 12
|
Time from the first dose of study drug to the first occurrence of a loss of asthma control (LOAC) event, as defined in the protocol. |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
Tidsram: Baseline to Week 12
|
Change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV₁), measured using standardized spirometry. |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
Tidsram: Baseline to Week 12
|
Change from Baseline in the Asthma Control Questionnaire (ACQ-5) |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
Tidsram: Baseline to Week 12
|
Change from Baseline in the Asthma Quality of Life Questionnaire (AQLQ) |
Baseline to Week 12
|
|
Plasma concentration of ENV-294
Tidsram: Baseline to Week 12
|
Plasma concentrations of ENV-294 will be measured at specified time points following oral administration of the investigational drug. |
Baseline to Week 12
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Gurpreet Ahluwalia, PhD, Enveda Therapeutics, Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- ENV-294-211
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Individual participant data (IPD) will not be shared. The data include sensitive health information that cannot be fully de-identified under current privacy standards, and the sponsor does not plan to make IPD available outside the study team. Summary results and aggregate data will be shared publicly as required by regulation.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .